Sensorimotor Neuropathy Market Report 2026

The sensorimotor neuropathy market size has grown strongly in recent years. It will grow from $8.0 billion in 2025 to $8.59 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to the rising prevalence of diabetes, the growing geriatric population, increasing awareness of neuropathy complications, the expansion of hospital and clinical infrastructure, and the increasing adoption of diagnostic technologies.

The sensorimotor neuropathy market size is expected to see strong growth in the next few years. It will grow to $11.3 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing research and development initiatives, rising investment in neurotherapeutics, increasing integration of genetic testing, expansion of personalized medicine solutions, and growing adoption of digital and remote monitoring technologies. Major trends in the forecast period include advancement in molecular genetic testing, development of minimally invasive therapies, innovations in neuroprotective drug design, increasing use of artificial intelligence in diagnostics, and expansion of patient-centric and telemedicine solutions.

The growing prevalence of diabetes is expected to drive the growth of the sensorimotor neuropathy market in the coming years. Diabetes is a chronic condition that affects how the body converts food into energy, characterized by elevated blood sugar levels due to impaired insulin production or function. Its prevalence is increasing as obesity rates rise, fueled by sedentary lifestyles and high consumption of processed, sugar- and fat-rich foods that reduce physical activity. Sensorimotor neuropathy management supports diabetic patients by providing targeted sensorimotor training to improve gait stability, ankle proprioception, and overall quality of life through better balance and reduced fall risk. For example, in 2025, the International Diabetes Federation, a Belgium-based health organization, reported that in 2024, approximately 589 million adults aged 20-79 were living with diabetes, with projections reaching 853 million by 2050, and over 80% of adults with diabetes residing in low- and middle-income countries. Consequently, the rising prevalence of diabetes is fueling growth in the sensorimotor neuropathy market.

Major companies in the sensorimotor neuropathy market are focusing on developing advanced diagnostic technologies, such as enhanced nerve conduction devices with improved user interfaces, to enable early detection, objective assessment, and monitoring of peripheral nerve damage. Nerve conduction devices with improved user interfaces combine quantitative nerve signal measurement with intuitive displays and guided workflows, allowing clinicians to perform accurate assessments efficiently at the point of care. For example, in January 2023, NeuroMetrix Inc., a US-based medical device company, launched the DPNCheck 2 peripheral neuropathy testing device, an enhanced nerve conduction system with an upgraded user interface. The device measures sural nerve conduction velocity and response amplitude - key biomarkers of peripheral neuropathy - and features a large, easy-to-use touchscreen display that guides clinicians through the test and presents real-time results more clearly than previous models. It also includes improved temperature compensation to ensure consistent performance across varied clinical environments.

In December 2024, electroCore Inc., a US-based commercial-stage bioelectronic medicine and wellness company, acquired NeuroMetrix Inc. for an undisclosed amount. Through this acquisition, electroCore aims to expand its bioelectronic medicine portfolio and increase patient access by integrating NeuroMetrix’s Quell wearable neuromodulation technology and leveraging its established commercial channels. NeuroMetrix Inc. is a US-based medical technology company specializing in the diagnosis and management of sensorimotor neuropathy.

Major companies operating in the sensorimotor neuropathy market are Johnson & Johnson, Merck & Co Inc., Pfizer Inc., Abbvie Inc., Sanofi S.A, Novartis AG, Astrazeneca plc, Abbott Laboratories, Glaxosmithkline plc, Eli Lilly Company, Takeda Pharmaceutical Company Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Biogen Inc., Intas Pharmaceutical Limited, Ucb S.A., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr.Reddy's Laboratories Limited, Cipla Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceutical Limited, Boehringer Ingelheim International GmbH, Otuska Pharmaceutical Co. Ltd.

North America was the largest region in the sensorimotor neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sensorimotor neuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sensorimotor neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are impacting the sensorimotor neuropathy market by increasing costs of imported diagnostic equipment, electrophysiology devices, genetic testing kits, and pharmaceutical raw materials. healthcare providers in north america and europe are most affected due to reliance on imported diagnostic technologies, while asia-pacific faces higher costs for advanced testing solutions. these tariffs are increasing diagnostic and treatment expenses. however, they are also encouraging regional manufacturing of medical devices, local diagnostic capacity expansion, and increased investment in cost-efficient care delivery models.

Sensorimotor neuropathy is a condition in which the nerves responsible for both movement and sensation are damaged, disrupting communication between the brain, muscles, and sensory organs. It often leads to muscle weakness, loss of coordination, numbness, and abnormal sensations in different parts of the body. This condition typically arises from metabolic disorders, autoimmune responses, infections, exposure to toxins, or hereditary factors.

The primary types of sensorimotor neuropathy include diabetic neuropathy, hereditary neuropathy, Charcot-Marie-Tooth disease, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), toxic neuropathy, and infectious neuropathy. Diabetic neuropathy refers to nerve damage caused by prolonged high blood sugar levels, affecting both sensory and motor functions, often leading to pain, numbness, and muscle weakness. The treatments include medications, physical therapy, occupational therapy, transcutaneous electrical nerve stimulation (TENS), and surgery. Diagnosis involves electromyography and motor nerve conduction tests, specialized DNA blood tests, molecular genetic testing, and others, and distribution occurs through hospital pharmacies, as well as retail and online pharmacy channels.

The sensorimotor neuropathy market consists of revenues earned by entities by providing services such as neurological diagnostic evaluation services, nerve conduction and electromyography testing services, neuropathy management and treatment planning services, physical and occupational rehabilitation therapy services, and long-term patient monitoring and follow-up care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The sensorimotor neuropathy market also includes sales of neuropathy diagnostic devices, nerve conduction testing equipment, electromyography systems, pain management medical devices, and rehabilitation support equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.